本文選題：痛瀉要方加減 + 雷貝拉唑��； 參考：《貴陽中醫(yī)學(xué)院》2015年碩士論文

【摘要】：目的：觀察痛瀉要方加減聯(lián)合雷貝拉唑治療肝郁脾虛證胃潰瘍患者的療效和血清IL-2、IL-6的變化,探討其可能作用機(jī)制和IL-2、IL-6在肝郁脾虛證胃潰瘍發(fā)病中的作用及臨床意義。方法：將60例肝郁脾虛證胃潰瘍患者隨機(jī)分為治療組和對照組。對照組采用根除Hp標(biāo)準(zhǔn)三聯(lián)療法2周后,繼服雷貝拉唑4周；治療組則在采用對照組治療方案的同時聯(lián)合痛瀉要方加減治療,療程亦為6周。治療結(jié)束后觀察臨床療效、證候積分變化、Hp根除情況、潰瘍半年復(fù)發(fā)率及不良反應(yīng)。并在治療前后檢測患者血清IL-2、IL-6,與15名體檢正常人對比,觀察其變化。結(jié)果：1、胃鏡療效：治療組與對照組比較,差異無顯著意義(P0.05)。2、中醫(yī)證候療效：治療組愈顯率、總有效率均高于對照組,差異有顯著意義(P0.05)。3、中醫(yī)證候積分比較：組內(nèi)比較,各組總積分,各證積分均較治療前明顯降低,差異有顯著意義(P0.05)。組間比較,治療后治療組總積分、各證積分(舌脈除外)均低于對照組,差異有顯著意義(P0.05)。4、根除Hp療效：治療后,治療組與對照組Hp根除率比較,差異無顯著意義(P0.05)；半年后治療組復(fù)發(fā)率明顯低于對照組,差異有顯著意義(P0.05)。5、患者血清IL-2、IL-6的變化：兩組患者治療前IL-2明顯降低,IL-6明顯升高,較之正常組差異有顯著意義(P0.05)。治療后治療組接近正常組,差異無統(tǒng)計意義(P0.05)；而對照組在治療后,較之正常組和治療組,差異仍有顯著意義(P0.05)。6、潰瘍復(fù)發(fā)率：治療組低于對照組,但差異無顯著意義(P0.05)。結(jié)論痛瀉要方加減聯(lián)合雷貝拉唑治療肝郁脾虛證胃潰瘍療效顯著,復(fù)發(fā)率低,毒副作用小,安全可靠。其作用機(jī)制可能是通過調(diào)節(jié)細(xì)胞因子水平而發(fā)揮治療作用。
[Abstract]:Objective: to observe the therapeutic effect of Tongxieyao decoction plus or minus rabeprazole in treating gastric ulcer of liver stagnation and spleen deficiency syndrome and the change of serum interleukin-6 (IL-6), and to explore the possible mechanism of the effect and the role and clinical significance of IL-2P IL-6 in the pathogenesis of gastric ulcer of liver stagnation and spleen deficiency syndrome.Methods: 60 patients with gastric ulcer of liver stagnation and spleen deficiency syndrome were randomly divided into treatment group and control group.The control group was treated with standard triple therapy for eradication of HP for 2 weeks, followed by rabeprazole for 4 weeks, while the treatment group was treated with the combination of Tongxie decoction and Tongxie decoction for 6 weeks.After the treatment, the clinical effect, symptom score, ulcer recurrence rate and adverse reaction were observed.The serum levels of IL-2 and IL-6 were measured before and after treatment, and compared with 15 normal controls.Results: there was no significant difference between the treatment group and the control group in the effect of gastroscopy. There was no significant difference between the treatment group and the control group. The curative effect of TCM syndromes: the total effective rate of the treatment group was higher than that of the control group, and the difference was significant (P0.05 路3). The comparison of TCM syndromes integral: comparison within the group,The total score of each group and the integral of each syndrome were significantly lower than those before treatment, and the difference was significant (P 0.05).After treatment, the total score and every syndrome score (except tongue pulse) in the treatment group were lower than those in the control group, and the difference was significant (P 0.05. 4). The curative effect of HP eradication: after treatment, the eradication rate of HP in the treatment group and the control group was higher than that in the control group.After treatment, the treatment group was close to the normal group, the difference was not statistically significant (P 0.05), while that in the control group was still significantly higher than that in the normal group and the treatment group. The recurrence rate of ulcer in the treatment group was lower than that in the control group, but there was no significant difference between the treatment group and the control group.Conclusion Tongxieyao decoction combined with rabeprazole in the treatment of gastric ulcer with liver stagnation and spleen deficiency syndrome has significant curative effect, low recurrence rate, small toxic side effect and safe and reliable.Its mechanism may be to regulate cytokine levels and play a therapeutic role.
【學(xué)位授予單位】：貴陽中醫(yī)學(xué)院
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R573.1

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 胡麗娟;;從歸經(jīng)理論觀察加味痛瀉要方治療腹瀉型腸易激綜合征肝郁脾虛證療效觀察[J];新中醫(yī);2014年11期

2 張聲生;趙魯卿;;消化性潰瘍的中醫(yī)辨證分型與治療[J];現(xiàn)代消化及介入診療;2011年04期

3 喻斌;彭益玲;;耳穴貼壓聯(lián)合加味痛瀉要方治療腸易激綜合征20例總結(jié)[J];湖南中醫(yī)雜志;2011年04期

4 鄭淑均;薛增印;;補(bǔ)中益氣湯合痛瀉要方加減治療肝郁脾虛腹瀉型腸易激綜合征療效觀察[J];河北中醫(yī)藥學(xué)報;2010年03期

5 宿廷敏;王敏娟;阮時寶;;白術(shù)的化學(xué)成分及藥理作用研究概述[J];貴陽學(xué)院學(xué)報(自然科學(xué)版);2008年02期

6 林麗艷;張慧云;何韶衡;;IL-6及其受體與炎癥性疾病關(guān)系的新進(jìn)展[J];中國熱帶醫(yī)學(xué);2008年04期

7 陳云志;呂建衛(wèi);劉安英;;痛瀉要方治療慢性膽囊炎56例臨床觀察[J];時珍國醫(yī)國藥;2008年03期

8 王彥剛;周琰;楊金國;蘇春芝;;痛瀉要方合小柴胡湯加減治療脂肪肝療效觀察[J];河北中醫(yī)藥學(xué)報;2007年01期

9 歐立娟;劉啟德;;陳皮藥理作用研究進(jìn)展[J];中國藥房;2006年10期

10 韓兆豐,陳蘭羽,尤春來;痛瀉要方抗實驗性胃潰瘍作用的實驗研究[J];遼寧中醫(yī)學(xué)院學(xué)報;2002年04期

，

本文編號：1744976